Our Products
CTI's product pipeline includes three
products in late-stage clinical development XYOTAX™,
pixantrone, and Brostallicin and several clinical and preclinical
product candidates that may address the therapeutic limitations
of conventional cancer therapies. Together, these drug
candidates represent our progress in making cancer
a more treatable disease.
Early development includes preclinical, phase I, and some phase
II clinical trials; late development includes phase IIb and later
clinical trials.
Posted Sept. 27, 2007
Copyright © 2004-2007 Cell Therapeutics,
Inc., Seattle, WA, USA. All rights reserved. "Making cancer
more treatable" is a registered mark of CTI.
|